Authors

• C Arendt
• Jason Coarse
• Paul Quinn
• Gary R. Lichtenstein (ORCID: https://orcid.org/0000-0003-0815-2044)
• Brian G. Feagan (ORCID: https://orcid.org/0000-0002-6914-3822)
• Edward V. Loftus (ORCID: https://orcid.org/0000-0001-7199-6851)
• Theresa Rosario-Jansen
• Scott D. Lee (ORCID: https://orcid.org/0000-0001-8936-8052)
• J. Stark (ORCID: https://orcid.org/0000-0001-7716-2727)
• Kaitlin Dehlin
• Samson Ng (ORCID: https://orcid.org/0009-0002-4494-2182)

Institutions

• Western University (CA)
• University of Washington (US)
• Ferring Pharmaceuticals (Switzerland) (CH)
• North Carolina Institute of Medicine (US)
• Clinical Research Consulting (US)
• Ferring Pharmaceuticals (United States) (US)
• Mayo Clinic in Arizona (US)
• UCB Pharma (United States) (US)
• University of Pennsylvania (US)
• UCB Pharma (Belgium) (BE)

Publication Details

Journal

Crohn s & Colitis 360

Published

2024-12-30

DOI

https://doi.org/10.1093/crocol/otae083

Citations

1

Primary Topic

Inflammatory Bowel Disease

Type

article

Field-Weighted Citation Impact

0.55

Funders

• UCB Pharma